Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved its global Phase 3 clinical trial plan for CT-P13 SC (Zymfentra) to evaluate efficacy and safety in patients with rheumatoid arthritis.
📊 [Key Disclosure Details & Financial Highlights]
- Overview
- Title: Approval of Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in the U.S. (Patients with Rheumatoid Arthritis)
- Application Date: June 18, 2024 (Local Time)
- Approval Date: August 17, 2024 (Local Time)
- Regulatory Authority: U.S. Food and Drug Administration (FDA)
- Board Resolution or Fact Confirmation Date: August 18, 2024 (Date the company confirmed no separate notification was received from the FDA by the review completion date)
- Clinical Trial Details
- Trial Phase: Global Phase 3 Clinical Trial
- Indication: Rheumatoid Arthritis (RA)
- Clinical Trial Registration Number: EudraCT number 2024-510945-32
- Objective: To demonstrate the superiority of CT-P13 SC over placebo in terms of efficacy as determined by clinical response according to ACR20 at Week 12
- Number of Subjects: 189 patients
- Trial Duration: Treatment period of 52 weeks
- Study Design: Randomized, placebo-controlled, double-blind, parallel-group
- Future Plans & Important Notes
- CT-P13 SC (Zymfentra) previously completed Phase 3 trials for adult ulcerative colitis and Crohn’s disease, obtaining market authorizations in major markets including the U.S. and Europe. This Phase 3 trial aims to expand its indication to rheumatoid arthritis.
- Statistically, the probability of a clinical-stage drug candidate receiving final market authorization is known to be around 10%, and commercialization plans may be modified or abandoned depending on trial outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring U.S. Phase 3 Trial Initiation and Subsequent Disclosures
This disclosure reports the formal approval from the U.S. FDA for the Phase 3 clinical trial plan of CT-P13 SC (Zymfentra) for rheumatoid arthritis. Tracking whether patient recruitment and dosing proceed as scheduled following this approval is important for assessing the actual execution of the trial toward indication expansion. Detailed updates can be verified in subsequent regulatory disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
